and polymorphisms in and around the gene encoding the HIV co-receptor CCR5, but the functional basis for the strongest of these associations, rs1015164A/G, is unknown. We found that rs1015164 marks variation in an activating transcription factor 1 binding site that controls expression of the antisense long noncoding RNA (lncRNA) CCR5AS. Knockdown or enhancement of CCR5AS expression resulted in a corresponding change in CCR5 expression on CD4 + T cells. CCR5AS interfered with interactions between the RNA-binding protein Raly and the CCR5 3′ untranslated region, protecting CCR5 messenger RNA from Ralymediated degradation. Reduction in CCR5 expression through inhibition of CCR5AS diminished infection of CD4 + T cells with CCR5-tropic HIV in vitro. These data represent a rare determination of the functional importance of a genome-wide disease association where expression of a lncRNA affects HIV infection and disease progression.
T he noncoding RNAs are classified either as small (<200 base pairs (bp)) or long (>200 bp) transcripts without protein coding potential. Long noncoding RNA (lncRNA) genes are numerous, exceeding the number of protein-coding genes, and are emerging as epigenetic regulators with a prominent role in health and disease. lncRNAs regulate gene expression, chromatin organization, cellular trafficking, RNA decay and translation. Notably, the localization, function, decay and turnover of proteins are also influenced by lncRNAs (reviewed in ref. 1 ). In several viral infections, cellular lncRNAs have been shown to regulate viral replication 2 , or cellular metabolic 3 and immune responses 4 .
A large number of intergenic single-nucleotide polymorphisms (SNPs) associate with human disease outcomes (genome-wide association study catalog; http://www.ebi.ac.uk/gwas), many of which are in or near lncRNA genes and may mark differential expression or function of the lncRNAs 5 . Recently, the influence of some of these SNPs on expression or function of lncRNA genes, their protein coding targets and/or disease outcomes has been demonstrated in cancer 6 , the chronic immune-mediated disorder celiac disease 7 and pneumococcal bacteremia 8 , but any potential role of lncRNA polymorphisms in viral infections remains uncharacterized.
Human chromosome 3p21-22 harbors a cluster of chemokine receptor genes, several of which can serve as co-receptors for human immunodeficiency virus type 1 (HIV-1) 9 . CCR5 is the major co-receptor of HIV, and variation in its expression influences the outcome of HIV-1 infection. Complete loss of CCR5 surface expression because of homozygosity for a 32-bp deletion in CCR5 (CCR5Δ32) results in resistance to HIV infection 10, 11 . There is a decrease in CCR5 surface expression on T cells among CCR5Δ32 heterozygous subjects compared with those carrying two functional copies of the gene 12, 13 . Additional SNPs and haplotypes have been shown to associate with CCR5 transcription, surface expression levels and HIV-1 susceptibility [14] [15] [16] [17] [18] . CCR5 surface expression levels influence multiple aspects of HIV pathogenesis and disease outcomes, such as HIV entry 12, 13 , viral load 19 , progression to AIDS 19 , neutralizing activity of HIV-1-specific antibodies 20 , immune reconstitution during highly active antiretroviral therapy 19, 21 and the treatment efficacy of CCR5 blockers and entry inhibitors 22 , where in each instance low CCR5 surface expression is protective. Genetic associations of CCR5 and CCR2 gene polymorphisms with HIV-1 pathogenesis are well established 16, [23] [24] [25] , including an intergenic SNP (rs1015164A/G) downstream of the CCRL2 gene, which showed a statistically significant genome-wide association with HIV infection outcomes in meta-analyses that collectively examined genotyping data from 6,315 patients infected with HIV-1 26 . The rs1015164 SNP was found to have a genome-wide effect independent of other SNPs in the region, including CCR5Δ32, after correction for ethnicity, gender and cohort (P = 1.5 × 10 −19 ). Here we show that this SNP is in close genomic proximity to RP-11-24F11.2, an antisense noncoding RNA gene that overlaps with CCR5 and marks expression of the transcript encoded by the gene. We termed this transcript CCR5AS. Our data reveal that higher expression levels of CCR5AS, as a consequence of a variant in an activating transcription factor 1 (ATF1) transcription factor binding site that rs1015164A marks, enhance CCR5 messenger RNA (mRNA) stability, thereby increasing CCR5 mRNA and cell surface expression, and providing the functional basis for the association between rs1015164A and lack of HIV control.
Results

The rs1015164 SNP associates with HIV outcome after infection.
The CCR5∆32 mutation is present almost exclusively in people of European descent and confers nearly complete protection from HIV infection in homozygotes and slower progression to AIDS in heterozygotes for the mutation 10, 11 . Other CCR5 variants that associate with outcome to HIV infection, including rs1015164, however, are present across many populations, and some of these affect CCR5 expression 13, [27] [28] [29] . Among 2,745 quantitative trait loci in a monocyte transcriptome-wide scan, rs1015164 was identified as a marker of CCR5 mRNA expression 30 . We tested for an effect of rs1015164 on viral load after HIV-1 infection in three ethnic groups: African Americans, Hispanics and Japanese. Although the rs1015164A allele was less frequent in the African American and Hispanic cohorts, and homozygous individuals were rare, patients carrying at least one rs1015164A allele (AA + AG) had considerably higher viral load (increase of 0.24 log 10 copies ml −1 for AA/ AG, P African American = 1.7 × 10 −9 ; increase of 0.58 log 10 copies ml −1 for AA/AG, P Hispanic = 9.0 × 10 −32 ; Fig. 1a ,b) and decreased CD4 + T cell counts (−67.1 cells μl −1 for AA/AG, P African American = 7.3 × 10 −9 ; −121.7 cells μl −1 for AA/AG, P Hispanic = 1.3 × 10 −11 ; Fig. 1c ,d) over time. These results extend the effect of rs1015164 beyond people of European descent as reported previously 26 to Hispanics and African Americans. The rs1015164A allele was also less frequent in a sampling of Japanese patients compared with Europeans ( Supplementary Fig. 1a ); nevertheless, the AA genotype was notably associated with higher viral loads in these patients ( Supplementary  Fig. 1b ), pointing to a uniform deleterious effect of rs1015164A in HIV-1 infection across distinct populations. The consistency of the rs1015164 effect across the populations tested speak to a single functional mechanism explaining these associations.
rs1015164 marks expression of a lncRNA, CCR5AS. The rs1015164 SNP maps to the 5′ upstream region of a noncoding RNA gene RP-11-24F11.2 ( Fig. 2a ), so we tested whether this gene was transcribed. We detected and quantified a lncRNA transcript in total RNA from peripheral blood lymphocytes (PBLs) by quantitative PCR (qPCR) using RP-11-24F11.2-specific primers as confirmed by sequencing of the amplicons. Because the noncoding RNA is transcribed from the antisense strand of the CCR5 gene, the lncRNA transcript was termed CCR5AS. The rs1015164A allele, which we found ( Fig. 1 ) and was previously found to associate with higher viral loads 26 , associated with higher expression levels of CCR5AS in PBLs (Fig. 2b ). Because the primary cellular targets for HIV are CD4 + T cells, we tested and observed an association of rs1015164 genotype with CCR5AS expression levels in this cell type specifically, as well ( Fig. 2c ). In addition, rs1015164 genotype showed a significant correlation with CCR5 cell surface expression in bulk memory CD4 + T cells (P = 0.02; Fig. 2d and Supplementary  Fig. 2a ) and effector memory CD4 + T cells (P = 0.02; Fig. 2d and Supplementary Fig. 2a ). The rs1015164 SNP also marks expression of CCR5AS (ENSG00000223552.1) in whole blood, colon, visceral adipose, heart, brain, subcutaneous adipose and lung tissue (https:// www.gtexportal.org/; Supplementary Fig. 2b ).
Amplification of the 3′ and 5′ ends of the CCR5AS transcript uncovered the presence of two different isoforms, which are identical at the 5′ end. The short isoform lacks exon 2 and has a truncated exon 4 ( Supplementary Fig. 2c ). Both isoforms are more abundant in the cytoplasmic fractions, relative to nuclear RNA fractions from CD4 + T cells and the Hut-78 human T cell lymphoma cell line, both of which express CCR5 and CCR5AS ( Supplementary Fig. 2d ). Although the transcript did not contain any open reading frames longer than 20 codons, studies have suggested that several lncRNAs may in fact encode short peptides 31 . To test this possibility, we analyzed the CCR5AS transcript sequence using phyloCSF (phylogenetic codon substitution frequency) 32 , a conservation-based method that estimates whether a multispecies nucleotide sequence alignment in a specific locus is more likely to represent a protein coding than a noncoding transcript. The low phyloCSF score (−98.7) of CCR5AS is more in line with that of other known noncoding RNAs than it is with that of known protein coding transcripts. No coding potential is predicted for the transcript by other methods such as RNAcode, coding potential assessment tool or small open reading frame riboseq coding (http://fantom.gsc.riken.jp/cat/) 33 .
CCR5AS enhances expression of the HIV co-receptor CCR5.
lncRNAs can affect the expression of nearby genes (reviewed in ref. 34 ). Given that the CCR5 gene is completely encompassed within the locus encoding CCR5AS (intron 2 specifically; Fig. 2a ), we tested whether CCR5AS may be involved in differential expression of CCR5. Only a proportion of peripheral blood CD4 + T cells express CCR5 (ref. 35 ). Nevertheless, CCR5AS expression levels in CD4 + T cells showed a significant, although moderate, positive correlation with levels of CCR5 mRNA expression (r = 0.42, P = 0.0001; Fig. 3a ). Stronger correlations between CCR5AS and CCR5 mRNA levels were observed in peripheral memory CD4 + T cells and monocytes (r = 0.72, P = 0.0001 and r = 0.82, P = 0.0001, respectively; Fig. 3b ,c), a larger proportion of which are known to express CCR5 35 . Two distinct short interfering RNAs (siRNAs) were used to silence CCR5AS expression ( Supplementary Fig. 3a,b ). The siRNA-mediated knockdown of CCR5AS resulted in reduced mRNA and surface expression of CCR5 ( Fig. 3d ,e and Supplementary Fig. 3c,d) , whereas overexpression of the CCR5AS short form increased mRNA and surface expression of CCR5 in primary CD4 + T cells ( Fig. 3f,g) , as did overexpression of the CCR5AS long form ( Supplementary Fig. 3e ,f). Taken together, these data indicate that CCR5AS might function as a regulator of CCR5 expression levels. Because siRNA-mediated downregulation of CCR5AS also reduced mRNA and cell surface expression of CCR5 in the Hut-78 T cell line ( Supplementary Fig.  4a ,b), Hut-78 cells were used to further probe the molecular mechanism of CCR5AS-mediated regulation of CCR5.
Binding of the CCR5AS transcript to Raly protects CCR5 mRNA from degradation. Cytoplasmic lncRNAs have been shown to affect expression of their targets posttranscriptionally (reviewed in ref. 36 ). We assessed the effect of CCR5AS knockdown on cellular CCR5 mRNA by estimating the decay rates of metabolically labeled CCR5 mRNA in Hut-78 cells treated with control siRNA (siCon1) or CCR5AS-targeting siRNA (siLnc1). The decay of CCR5 mRNA was considerably faster in siLnc1-treated cells ( Supplementary Fig. 4c ), indicating that silencing of CCR5AS results in degradation of CCR5 mRNA.
Cytoplasmic lncRNAs can function as sponges of microRNAs (miRNAs) and rescue expression of the miRNA targets. CCR5AS and CCR5 transcripts share binding sites for two miRNAs (miR-197 and miR-1224), but in vitro-transcribed CCR5AS lncRNA with mutations in the binding sites of either or both of these miRNAs still enhanced CCR5 mRNA expression ( Supplementary Fig. 5 ), indicating that CCR5AS-mediated regulation of CCR5 expression is independent of the shared miRNA binding sites.
There are several examples of lncRNAs that alter gene expression via the recruitment or sequestration of proteins involved in posttranscriptional regulation of translation 37 or mRNA stability [38] [39] [40] . To determine the protein binding partners of CCR5AS lncRNA, we carried out RNA antisense purification using a CCR5AS-specific probe that enriched CCR5AS transcript 1,000-fold (Fig. 4a ). The proteins pulled down were separated by polyacrylamide gel electrophoresis (PAGE), and prominent bands with differential intensity were analyzed by mass spectrometry to identify the proteins that bound specifically to CCR5AS (Fig. 4b ). The Raly RNA binding protein (RBP) was identified specifically in the CCR5AS-specific pulldown, but not the scrambled control pulldown (Fig. 4c ), a finding that was further confirmed in an antisense pulldown using immunoblotting ( Supplementary Fig. 6a ). In silico analysis also showed strong prediction of Raly binding to both isoforms of CCR5AS ( Supplementary  Fig. 6b ). To confirm the endogenous CCR5AS interaction with Raly, we performed RNA immunoprecipitation (RIP), in which a version of Raly protein tagged with Myc at the C-terminal end of the protein coding sequence was overexpressed. Myc-tagged proteins were immunoprecipitated using anti-Myc-coated magnetic beads, and immunoprecipitation of Raly protein was confirmed by western blot ( Supplementary Fig. 6c ). Protein-bound RNA was analyzed by qPCR, showing that endogenous CCR5AS was enriched substantially in the Raly Myc-pulldown (Raly-IP) as compared with control IgG-coated beads (IgG-IP; Fig. 4d ). These results indicate that CCR5AS RNA interacts with Raly.
Given the interaction between Raly and CCR5AS, we tested for an effect of Raly on the CCR5 expression level. Knockdown of Raly using a Raly-targeting siRNA (siRaly) was confirmed by immunoblot ( Supplementary Fig. 6d ). The suppressive effect of Raly on CCR5 expression was evident by enhanced mRNA expression and surface expression of CCR5 72 h after siRNA-mediated knockdown of Raly protein ( Fig. 5a,b ), a finding that was concordant with in silico analysis that strongly predicted binding of Raly to the CCR5 3′ untranslated region (UTR) (Fig. 5c ). These findings were further to unadjusted viral load or CD4 counts. Analysis of the log 10 -transformed HIV viral load and CD4 + T cell counts at each time point was performed using the lmer function in R. We allowed for random effects because of the time after enrollment. Likelihood ratio P values using the ANOVA function in R were calculated to compare nested models fit under a maximum-likelihood scenario.
supported by cloning the CCR5 3′ UTR downstream of Renilla luciferase in a dual-luciferase vector psicheck2 ( Supplementary Fig.  6e ), transfecting the construct into Raly-inhibited cells and testing the effect of Raly inhibition on luciferase reporter activity. The siRNA-mediated knockdown of Raly protein increased the luciferase activity of the CCR5 3′ UTR construct as compared with that in the siCon-transfected cells (Fig. 5d ). Thus, depletion of Raly enhances CCR5 expression. We hypothesized that CCR5AS may enhance stability of CCR5 mRNA by sequestering Raly, thereby keeping it from binding to the CCR5 3′ UTR and degrading CCR5 transcripts. We tested directly whether the interaction between CCR5AS and Raly interferes with binding of Raly to the CCR5 3′ UTR using Hut-78 cells transfected with Myc-tagged Raly plus either siLnc1 (to knock down CCR5AS mRNA) or the control siCon1. Pulldown of Myc-tagged Raly protein from cellular lysates (input) by immunoprecipitation with anti-Myc (Raly-IP), but not control IgG (IgG-IP), was confirmed by western blot ( Supplementary Fig. 6f ). Changes in the association between Raly and CCR5 3′ UTR with or without silencing of CCR5AS were then measured by RIP. Enrichment of CCR5AS and CCR5 3′ UTR in the Raly-bound RNA was estimated by qPCR. CCR5AS was found to be highly enriched in Raly pulldown from the siCon1treated cells, but absent in Raly pulldown from the siLnc1-transfected cells in which CCR5AS was silenced ( Supplementary Fig. 6g ). As predicted by in silico analysis ( Fig. 5c ), CCR5 3′ UTR was also found to be enriched in the Raly pulldown in siCon1-treated cells; however, association between the CCR5 3′ UTR and Raly was considerably enhanced upon CCR5AS knockdown (Fig. 6a ). Further, transfection of Hut-78 cells with vector containing the CCR5 3′ UTR downstream of Renilla luciferase ( Supplementary Fig. 6e ), followed by CCR5AS knockdown, resulted in diminished luciferase activity of the CCR5 3′ UTR construct as compared with the control cells ( Fig. 6b ). We assessed the effect of Raly knockdown on cellular CCR5 mRNA stability by estimating the decay rates of metabolically labeled CCR5 mRNA in cells treated with siCon or siRaly. The decay of CCR5 mRNA was notably slower in siRaly-treated cells ( Supplementary Fig. 6h ), indicating that silencing of Raly results in increased stability of CCR5 mRNA. Overall, the data indicate that CCR5AS interferes with binding of Raly to the CCR5 3′ UTR (Fig. 6c ), thereby enhancing CCR5 mRNA stability. 
Knockdown of CCR5AS reduces the susceptibility of CD4 + T cells to HIV-1 infection. The potential impact of CCR5ASmediated regulation of CCR5 expression levels on HIV infection of
CD4 + T cells was tested using an in vitro infection assay in which purified CD4 + T cells were transfected with siRNA to downregulate CCR5AS (siLnc1) or were transfected with siCon1). The CCR5AS siRNA-transfected cells were infected with R5-tropic (CCR5dependent) or vesicular stomatitis virus-glycoprotein (VSV-G) pseudotyped (CCR5-independent) HIV-1 vectors encoding a green fluorescent protein (GFP). The proportions of GFP + cells in the siLnc1-treated cells were compared with that of the siCon1-treated cells. The siRNA-mediated silencing of CCR5AS led to 25-50% reduction in the proportion of GFP + T cells in the cultures infected with the R5-tropic virus, whereas downregulation of CCR5AS did not affect the proportion of GFP + cells in the cultures infected with the CCR5-independent VSV-G pseudotyped vector ( Fig. 7a and Supplementary Fig. 7a-f) . Similarly, primary CD4 + T cells from rs1015164AA/AG donors showed a considerable increase in infection with R5-tropic virus as compared with CD4 + T cells from donors with the rs1015164GG genotype (P = 0.02; Fig. 7b and Supplementary Fig. 7b-d) , but there was no difference in infection with the VSV-G pseudotyped vector in donors with these rs1015164 genotypes. These data indicate that silencing of CCR5AS reduces infection of T cells with a CCR5-dependent virus.
Our results suggest that the rs1015164A allele marks high CCR5AS expression. High CCR5AS enhances CCR5 expression posttranscriptionally by sequestering the RBP Raly from the CCR5 3′ UTR and thereby protecting CCR5 mRNA from Raly-mediated decay, resulting in higher surface expression of CCR5, enhanced HIV infection and higher HIV-1 viral loads ( Supplementary Fig. 8 ).
rs2027820 is in perfect linkage disequilibrium with rs1015164 and influences the binding of ATF1. Bioinformatics analysis indicated that the rs1015164 SNP does not appear to be in a transcription factor binding site. There are, however, additional SNPs located upstream of CCR5AS (rs35937775) and in the intronic regions of CCR5AS (rs6441975, rs2027820, rs2373232) that are in perfect/near-perfect linkage disequilibrium (r 2 = 0.9-1) with rs1015164 in Europeans, Japanese and Africans (http://www. internationalgenome.org). Only one of these four SNPs, rs2027820, which is located in the first intron of CCR5AS, was predicted to lie within a transcription factor binding site and alter binding potential. The minor allele rs2027820G (in linkage disequilibrium with rs1015164A, which associates with higher CCR5AS expression levels; r 2 = 1 in Europeans and Africans, r 2 = 0.94 in Japanese) maintains an intact binding site for ATF1 (ref. 41 ) and is therefore predicted to enhance CCR5AS expression, whereas the major allele, rs2027820A (in linkage disequilibrium with rs1015164G), disrupts the binding site. The presence of an ATF1 binding site within a sequence containing the rs2027820G variant was confirmed by electrophoretic mobility shift assay using rs2027820G versus rs2027820A oligonucleotides (Fig. 8a) . As predicted, the A variant had greatly diminished binding compared with the G variant using Jurkat and HeLa nuclear extracts, as well as nuclear extracts from HEK293 cells transfected with ATF1. We further tested the enhancer effect of the rs2027820 alleles using a luciferase reporter construct. A 1,000-bp fragment immediately upstream of the transcription start site of CCR5AS and a 500-bp intronic fragment containing the rs2027820A/G polymorphic site were cloned upstream and downstream of the firefly luciferase gene, respectively (Fig. 8b) . Relative luciferase activity of the construct containing rs2027820G (intact ATF1 binding site) was considerably higher as compared with the construct containing rs2027820A (disrupted ATF1 binding site) (Fig. 8c) . These data support a model in which the CCR5AS intronic rs2027820 variant, which is in virtually perfect linkage disequilibrium with rs1015164, regulates expression of CCR5AS through differential binding of ATF1.
Discussion
The chemokine receptor gene cluster on human chromosome 3 encodes co-receptors for HIV-1, including the major co-receptor CCR5. Multiple independent candidate gene approaches and subsequent genome-wide studies have identified clear associations between polymorphisms within/near to CCR5, most prominently the CCR5∆32 mutation, and outcomes of HIV infection. Reduction or absence of CCR5 expression due to heterozygosity or homozygosity for CCR5∆32, respectively, also associates with hepatitis B virus (HBV) recovery 42 , whereas increased risk for fatal West Nile virus infection associates with homozygosity for this mutation 43 , indicating the general importance of CCR5 expression levels in the immune response to viral infection. The work presented here demonstrates a mechanism of differential CCR5 regulation through the expression level of a lncRNA, CCR5AS. Our results reveal that a variant located upstream of CCR5AS, rs1015164A/G, associates with CCR5AS expression. High expression of CCR5AS (marked by rs1015164A) enhances CCR5 expression posttranscriptionally by sequestering the RBP Raly, inhibiting the binding of Raly to the CCR5 3′ UTR, and thereby protecting CCR5 mRNA from Raly-mediated decay. Interestingly, the CCR5AS lncRNA sequence, as well as its genomic position with respect to the CCR5 gene, is conserved in nonhuman primates, raising the possibility that its regulatory function may also be conserved. The rs1015164A/G variant has been shown to have a genomewide notable effect on HIV infection outcomes in people of European ancestry, and its effect is independent of CCR5Δ32 and other polymorphisms in the region 26 . We extend these studies showing a deleterious effect of rs1015164A in untreated African Americans, Hispanics and Japanese with HIV infection, in whom the CCR5Δ32 mutation is virtually absent. Thus, differential CCR5AS expression may be the primary means for regulating CCR5 expression levels worldwide. Although CCR5 is not a receptor for HBV, CCR5Δ32 has been shown to associate with spontaneous recovery of HBV 42 , apparently through immunological mechanisms 44, 45 . The rs1015164 genotype may also associate with outcome after HBV infection in a manner consistent with lower CCR5 expression (that is, rs1015164G) conferring protection, because we observed a trend toward enhanced HBV recovery with increasing copy number of rs1015164G (P for trend = 0.04; data not shown). These data test was used for statistical comparisons, and the two-tailed P value is indicated. c, In silico prediction of the interaction between the CCR5 transcript and the Raly protein was done using a freely available algorithm (http://service.tartaglialab.com), which integrates properties of protein and RNA structures into overall binding propensity. The interaction score predicts global and local interactions between RBP and lncRNA. A high interaction score (~3) predicts a strong interaction between Raly protein and CCR5 transcript in the 3′ UTR. d, CCR5 3′ UTR was cloned downstream of Renilla luciferase into a dual-luciferase reporter psicheck2 vector. Hut-78 cells were transfected with either the nontargeting siCon or siRaly. Seventy-two hours after siRNA transfection, the CCR5 3′ UTR luciferase constructs were transfected into siCon or siRaly transfected Hut-78 cells. Twenty-four hours after transfection of the luciferase constructs, the cells were lysed and luciferase activity was measured. Renilla and firefly luciferase activity were estimated by dual-luciferase assays and presented as the normalized ratio of Renilla versus firefly luciferase activity. The data represent six replicates in each group from two independent experiments. The mean ± s.e.m. are depicted as horizontal and vertical bars for each group, respectively. Nonparametric Wilcoxon-Mann-Whitney tests were used for statistical comparisons, and the two-tailed P value is indicated. suggest a general importance of CCR5 expression levels and the mechanisms responsible for this differential regulation in diseases where CCR5 contributes to viral entry and/or the immune response.
The rs1015164 SNP is intergenic and is not predicted to be located in a transcription factor binding site; therefore, it is unlikely to be directly responsible for differential CCR5AS expression levels. However, a variant located in the first intron of CCR5AS, rs2027820, may directly affect expression levels of this gene, because it is located within a binding site for the transcription factor ATF1 and it is in virtually perfect linkage disequilibrium with rs1015164. ATF1 belongs to the cyclic adenosine monophosphate-regulated enhancer-binding family of transcription factors and is expressed in a wide variety of cell types 41 . We show that rs2027820G, which is in linkage disequilibrium with rs1015164A, allows binding of ATF1 and enhances protein expression in a luciferase assay relative to rs2027820A, indicating that the rs2027820G variant enhances CCR5AS expression levels, whereas the A variant confers poor binding of ATF1 and relatively poor expression of CCR5AS.
The majority of lncRNAs are in low abundance and localize to the nucleus, where they participate in transcriptional regulation through diverse mechanisms (reviewed in ref. 46 ). However, some localize to the cytoplasm, which we have observed for CCR5AS. Whereas cytoplasmic lncRNAs can modulate mRNA stability or translation (reviewed in refs. 36, 47 ) by directly binding to their mRNA targets, others harbor miRNA binding sites that are in common with those present in the protein-coding mRNA targets of the miR-NAs. This competitive sequestration or 'sponging' of the miRNAs protects the protein-coding mRNA targets from miRNA-mediated repression. Similarly, lncRNAs can serve as 'decoys' of RBPs, sequestering RBPs from mRNA, and thereby regulating mRNA splicing, decay or translation. lncRNA-mediated modulation of the molecular and spatial availability of RBPs has been shown to affect cell cycle, transformation, differentiation and the immune response. We showed that CCR5AS behaves as a decoy for the RBP Raly, preventing its binding to and repression of CCR5 such that the expression levels of these two RNA species are positively correlated. Surveys of published GWAS show that most disease or traitassociated polymorphisms occur in noncoding regions 48 with an enrichment in regulatory elements or expression quantitative trait loci 49 , suggesting that the basis for these disease associations are due in part to regulation of gene expression. Only 3% of the entire transcriptome is protein coding 50 , signifying the vast predominance of noncoding RNAs in the human transcriptome. Thus, it is possible that a sizable portion of previously identified intergenic GWAS SNPs could be marking variation in function or expression of noncoding RNAs.
The functional explanations for the vast majority of disease-associated SNPs identified by GWAS remain unknown. Here we provide the underlying biological basis for the genome-wide association between the rs1015164A/G variant and outcome after HIV infection, establishing a foundation for potential therapeutic interventions.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41590-019-0406-1. Fig. 8 | ATF1 binds rs2027820G more strongly than rs2027820A. a, An electrophoretic mobility shift assay was performed with 32 P-labeled oligonucleotides containing the core binding sequence for ATF1 containing the A or G variant of rs2027820. Nuclear extracts of recombinant human ATF1-transfected HEK293, or untransfected HeLa or Jurkat cells were incubated with each of the oligonucleotides (indicated as A or G) in the presence of a control antibody (Ctl for ATF1-transfected HEK293 extracts was specific for Sp1; Ctl for HeLa and Jurkat extracts was nonspecific IgG) or ATF1-specific antibody (ATF1). The presence of a shift (marked Atf1) indicates that the oligonucleotide binds a protein contained in the corresponding nuclear extract. A supershift is observed when an anti-ATF1 is added, but not when an Sp1 antibody or control IgG is added. A single experiment was performed. b, A fragment of 1,000 bp immediately upstream of the transcription start site of CCR5AS and a 500-bp intronic fragment containing the rs2027820A/G polymorphic site were cloned upstream and downstream of the firefly luciferase gene, respectively, in a PGL3-basic vector. The firefly luciferase constructs with basic vector (no promoter), control vector (SV40 promoter), IntA (rs2027820A) and IntG (rs2027820G) were transfected along with Renilla luciferase encoding vector in a 293T derivative cell line (Lenti-X). c, Luciferase activity was measured 24 h posttransfection, and relative activity of firefly luciferase normalized to Renilla was determined as relative light units. The IntG vector showed substantially higher luciferase activity as compared with the IntA vector. The data represent three replicates in each group from two independent experiments. The means ± s.e.m. are depicted as horizontal and vertical bars for each group, respectively. Statistical significance was determined using a nonparametric t-test, and the two-tailed P value is indicated.
